Optimizing the synergy between low-dose radiation and immunotherapy in metastatic melanoma: a critical analysis of current understanding

Abdullah Saad

My review of recent analyses exploring therapeutic synergies between low-dose radiation therapy (LDRT) and immunological interventions in advanced melanoma has prompted several important considerations.[1] Although the original review provides valuable insights, certain critical aspects warrant deeper examination.

The immunomodulatory mechanisms of LDRT, though well-documented, raise questions about optimal treatment sequencing. Recent investigations have demonstrated that the precise timing of immunotherapeutic interventions significantly influences clinical outcomes, particularly regarding immune cell activation and modifications to the tumour microenvironment.[2] This temporal relationship deserves further research attention.

While the discussion of immune checkpoint inhibitor combinations is valuable, it represents only a portion of the emerging therapeutic approaches. Novel treatments, such as engineered T-cell therapies and oncolytic viral interventions, have shown promising efficacy—particularly in managing central nervous system metastases.[3] These innovations fundamentally changed our approach to melanoma management.

Patient stratification methodologies merit further exploration. Advances in computational imaging and artificial intelligence-driven biomarker discovery have refined patient selection for combination therapies.[4] Moreover, investigating potential synergy between tumour-treating fields and LDRT could yield further insights, given growing evidence of their complementary effects.[5]

The authors deserve recognition for their thorough examination of systemic immune responses and balanced integration of experimental and clinical perspectives. The analysis of cytokine interactions with LDRT commendable academic rigour and depth.

As immunotherapy continues to evolve rapidly, comprehensive reviews like this are crucial for guiding future research directions. The authors successfully navigated this complex therapeutic landscape while maintaining both scientific accuracy and clinical relevance.

This thoughtful analysis will undoubtedly catalyse further investigations into optimized combination strategies to enhance patient outcomes.

DOI: https://doi.org/10.47391/JPMA.30429

Disclaimer: None.

Conflict of Interest: None.

Source of Funding: None.

References

1. Nardone V, D'Auria F, De Rosa F, Zhang X, Huang X. Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects. Ann Med Surg (Lond) 2023;74:103169. doi: 10.1016/j.amsu.2022.103169.
2. Lee Y, Ahn E, Karam SD, Wang Y, Zhang X. The impact of sequencing immunotherapy and radiation therapy on treatment outcomes in cancer. Cancer Immunol Res 2023;11:154-65. doi: 10.1158/2326-6066.CIR-22-0640.
3. Liu Y, Zheng Y, Zhang X, Wang Y, Huang X. Next-generation immunotherapy approaches in melanoma: CAR-T cells and oncolytic viruses. J Immunother Cancer 2023;11:e005234. doi: 10.1136/jitc-2022-005234.
4. Xu Y, Wang Y, Huang X, Zhang X, Liu Y. Recent developments in radiomics for tumour prediction and treatment selection. Nat Rev Clin Oncol 2023;20:700-15. doi: 10.1038/s41571-023-00774-0.
5. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumour microenvironment. Nat Immunol 2024;25:26-37. doi: 10.1038/s41590-023-01634-6.

2nd Year MBBS Student, Jinnah Sindh Medical University, Karachi, Pakistan.
Correspondence: Abdullah Saad. **Email:** abdullahsaad2005@yahoo.com
ORCID ID: 0009-0003-6973-8951

Submission complete: 11-03-2025 **First Revision received:** 26-03-2025
Acceptance: 16-04-2025 **Last Revision received:** 15-04-2025

AUTHORS' CONTRIBUTIONS:
AS: Concept, literature review, writing, revision and agreement to be accountable for all aspects of the work.